It’s been two years since Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) secured approval for a new and highly effective treatment for people suffering with a serious form of eczema. In that time, the Regeneron-Sanofi drug, called Dupixent, has grown into a commercial blockbuster.

On Monday, Dermira (DERM), a small biotech firm based on Menlo Park, Calif., announced clinical trial results for a new drug called lebrikizumab that alleviated the signs and symptoms of serious eczema far greater than a placebo.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy